rheumatoid arthritis

Pfizer's solo Xeljanz can't match AbbVie's Humira in big RA head-to-head miss

Sanofi's Brandicourt announces at JPM that plant issues leading to CRL for RA drug have been fixed

Australia's Mesoblast says stem cell RA candidate aids post biologic therapy in PhII